Centre Hospitalier de Luxembourg
- Address
- lock Available on a paid plan
Virus Diseases
At Centre Hospitalier de Luxembourg, clinical research in virus diseases focuses on SARS-CoV-2 and COVID-19, with studies centered on improving care for hospitalized patients. The trials are designed to assess whether new or repurposed treatments can help reduce disease worsening and support recovery in moderate to severe infection.
- Evaluating treatment effectiveness in hospitalized patients with moderate COVID-19
- Studying ways to prevent progression in SARS-CoV-2 infection
- Assessing interventions for severe and critical coronavirus disease outcomes
These studies reflect a strong infectious disease and critical care focus within the site’s Intensive Care Unit, with the aim of identifying therapies that can improve outcomes in patients most affected by the pandemic.
Hospital-Based COVID-19 Research
This hospital-based research program at Centre Hospitalier de Luxembourg is built around COVID-19 treatment evaluation in patients requiring inpatient care. The clinical trials aim to determine whether adding specific therapies to standard care can improve survival and reduce the risk of clinical deterioration.
- Testing new treatment approaches for moderate coronavirus disease
- Comparing therapies intended to lower death risk in severe COVID-19
- Supporting evidence-based care for immunocompromised patients with serious infection
The site’s work in emerging infections and intensive care medicine contributes to better understanding of how to manage hospitalized patients during high-risk stages of viral disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Novadip Biosciences2active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novadip Biosciences3trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 3 other sites in Luxembourg
Therapeutic Area Benchmark — Luxembourg
Select a therapeutic area to compare against other sites in Luxembourg.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Luxembourg
Market Share
Country: Luxembourg
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Hospitalier de Luxembourg
lock Showing 1 of 7 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy and Safety of AXL-Inhibitor bemcentinib for the Treatment of Moderate COVID-19 (AXL-SolidAct) | Oslo University Hospital HF | Phase II | Not Recruiting | Aug 2022 | Dec 2023 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Prasinezumab | 2 | Unknown | 2021-05-11 | 2021-05-11 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.